39
Participants
Start Date
April 4, 2016
Primary Completion Date
February 25, 2020
Study Completion Date
March 20, 2020
Lenvatinib
"All patients will receive lenvatinib 24 mg orally once daily at almost the same time. The treatment will be started within 1 week after enrollment. 1 cycle consists of 4 weeks.~The administration will be continued until patients meet withdrawal criteria. If any toxicity manifested that cannot be ruled out causal association with the study drug, drug withdrawal or dosage reduction will be conducted in accordance with drug withdrawal/dosage reduction criteria."
Nagoya University Hospital, Nagoya
Fujita Health University Hospital, Toyoake
IUHW Ichikawa Hospital, Ichikawa
National Cancer Center Hospital East, Kashiwa
Japanese Red Cross Narita Hospital, Narita
Kuma Hospital, Kobe
Kobe Univbersity Hospital, Kobe
University of Tsukuba Hospital, Tsukuba
Iwate Medical University Hospital, Morioka
Kitasato University Hospital, Sagamihara
Showa University Northern Yokohama Hospital, Yokohama
Kanagawa Cancer Center, Yokohama
Miyaghi Cancer Center, Natori-shi
Tohoku University Hospital, Sendai
Shinsyu University School of Medicine Department of Surgery, Matsumoto
Nara Hospital Kinki University Faculty of Medicine, Ikoma
Nara Medical University, Kashihara
Osaka Police Hospital, Osaka
Osaka City University Graduate School of Medicine and Faculty of Medicine, Osaka
Nippon Medical School Hospital, Bunkyo-ku
The Cancer Institute Hospital of JFCR, Koto-ku
Ito Hospital, Shibuya-ku
Tokyo Medical University Hospital, Shinjuku-ku
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
OTHER